Skip to main content

Advertisement

SpringerLink
Log in

Opportunities for Typhoid Vaccination in India

  • Perspective
  • Published:
Indian Pediatrics Aims and scope Submit manuscript

Abstract

Typhoid fever, an infection with potentially life threatening complications, is responsible for 11 to 21 million illness episodes and 145,000 to 161,000 deaths each year globally. India is a high burden country and also faces the challenge of antimicrobial resistance, which further narrows treatment options. This review analyzes the need for typhoid vaccination in India, and appraises the evidence on efficacy, immunogenicity and cost-effectiveness of currently available typhoid vaccines. In 2018, WHO prequalified the first typhoid conjugate vaccine Vi-TT and recommended it for children aged 6–23 months, along with measles vaccine at 9 or 15 months of age through the expanded programme on immunization. With the high endemicity of typhoid in India and the proven cost-effectiveness of the conjugate vaccine, a roll-out of typhoid vaccine should be considered at the earliest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. Progress on drinking water, sanitation and hygiene: 2017 update and SDG baselines. Available from: http://www.who.int/water_sanitation_health/publications/jmp-2017/en/. Accessed June 29, 2018.

  2. Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, et al. Burden of typhoid fever in low-income and middle-income countries: A systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2:e570–80.

    Article  PubMed  Google Scholar 

  3. Antillón M, Warren JL, Crawford FW, Weinberger DM, Kurum E, Pak GD, et al. The burden of typhoid fever in low- and middle-income countries: A meta-regression approach. PLoS Negl Trop Dis. 2017;11:e0005376.

    Article  PubMed  PubMed Central  Google Scholar 

  4. John J, Van Aart CJ, Grassly NC. The burden of typhoid and paratyphoid in India: systematic review and meta-analysis. PLoS Negl Trop Dis. 2016;10:e0004616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ochiai RL. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008;86:260–8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mogasale V, Desai SN, Mogasale VV, Park JK, Ochiai RL, Wierzba TF. Case fatality rate and length of hospital stay among patients with typhoid intestinal perforation in developing countries: A systematic literature review. PLoS One. 2014;9:e93784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat Genet. 2015;47:632–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio. 2018;9:e00105–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Steele AD, Hay Burgess DC, Diaz Z, Carey ME, Zaidi AKM. Challenges and opportunities for typhoid fever control: A call for coordinated action. Clin Infect Dis. 2016;62:S4–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Typhoid vaccines: WHO position paper - August 2000. Wkly Epidemiol Recd. 2000;75:257–64.

  11. Typhoid vaccines: WHO position paper - February 2008. Wkly Epidemiol Recd. 2008;83:49–59.

  12. World Health Organisation. Background Paper to SAGE on Typhoid Vaccine Policy Recommendations, 2017. Available from http://www.who.int/immunization/sage/meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B.pdf. Accessed August 12, 2018.

  13. Typhoid vaccines: WHO position paper-March 2018. Wkly Epidemiol Recd. 2018; 93:153–72.

  14. World Health Organization. The immunological basis for immunization series: module 20: salmonella enterica serovar Typhi (typhoid) vaccines. 2011. Available from: http://www.who.int/iris/handle/10665/44752. Accessed August 12, 2018.

  15. Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390:2472–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, et al. Efficacy and safety of Vi-tetanus toxoid conjugated typhoid vaccine (PedaTyphTM) in Indian children: School based cluster randomized study. Hum Vaccines Immunother. 2016;12:939–45.

    Article  Google Scholar 

  17. Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: A multicenter, 2-cohort, open-label, doubleblind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61:393–402.

    Article  CAS  PubMed  Google Scholar 

  18. Voysey M, Pollard AJ. Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV). Clin Infect Dis. 2018;67:18–24.

    Article  CAS  PubMed  Google Scholar 

  19. Antillón M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017;35:3506–14.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lo NC, Gupta R, Stanaway JD, Garrett DO, Bogoch II, Luby SP, et al. Comparison of strategies and incidence thresholds for vi conjugate vaccines against typhoid fever: A cost-effectiveness modeling study. J Infect Dis. 2018;218:S232–42.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Andrews JR, Baker S, Marks F, Alsan M, Garrett D, Gellin BG, et al. Typhoid conjugate vaccines: A new tool in the fight against antimicrobial resistance. Lancet Infect Dis. 2019;19:e26–30.

    Article  CAS  PubMed  Google Scholar 

  22. Balasubramanian S, Shah A, Pemde HK, Chatterjee P, Shivananda S, Guduru VK, et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines And Immunization Practices (ACVIP) Recommended Immunization Schedule (2018-19) and Update on Immunization for Children Aged 0 Through 18 Years. Indian Pediatr. 2018; 55:1066–74.

    Article  CAS  PubMed  Google Scholar 

  23. GAVI 2018. New Typhoid Vaccine to Receive GAVI Support. Available from: https://www.gavi.org/library/news/statements/2018/new-typhoid-vaccine-to-receive-gavi-support/. Accessed August 12, 2018.

  24. World Health Organizationý. Typbar TCV® from Bharat Biotech, world’s first typhoid conjugate vaccine prequalified by WHO. 2018. Available from: http://www.who.int/medicines/news/2017/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf. Accessed August 12, 2018.

  25. NSSEFI Collaborators, John J, Bavdekar A, Rongsen-Chandola T, Dutta S, Kang G. Estimating the incidence of enteric fever in children in India: A multi-site, active fever surveillance of pediatric cohorts. BMC Public Health. 2018;18:594.

    Article  Google Scholar 

  26. Meiring JE, Gibani M, Basnyat B, Bentsi-Enchill AD, Clemens J, Darton TC, et al. The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UK. Vaccine. 2017;35:5081–8.

    Article  PubMed  Google Scholar 

  27. Coalition against typhoid. Navi Mumbai Municipal Corporation launches the world’s first public-sector typhoid conjugate vaccine campaign. 2018. Available from: http://www.coalitionagainsttyphoid.org/navi-mumbai-municipal-corporation-launches-the-worlds-first-public-sector-typhoid-conjugate-vaccine-campaign/. Accessed December 22, 2018.

  28. Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018;CD001261.

  29. Klugman KP. Usefulness of the serial measurement of Vi antibodies. Clin Infect Dis. 2018;67:25–6.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Lin FYC, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344:1263–9.

    Article  CAS  PubMed  Google Scholar 

  31. Lanh MN, Van Bay P, Ho VA, Thanh TC, Lin FYC, Bryla DA, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med. 2003;349:1390–1.

    Article  CAS  Google Scholar 

Download references

Funding

Funding: None; Competing interests: None stated.

Author information

Authors and Affiliations

  1. Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India

    Manikandan Srinivasan, Kulandaipalayam Natarajan Sindhu & Gagandeep Kang

  2. Department of Community Health, Christian Medical College, Vellore, India

    Jacob John

  3. The Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, 632 002, Tamil Nadu, India

    Gagandeep Kang

Authors
  1. Manikandan Srinivasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kulandaipalayam Natarajan Sindhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacob John
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gagandeep Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gagandeep Kang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Srinivasan, M., Sindhu, K.N., John, J. et al. Opportunities for Typhoid Vaccination in India. Indian Pediatr 56, 453–458 (2019). https://doi.org/10.1007/s13312-019-1566-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13312-019-1566-7

Keywords

Search

Navigation